-
Acinetobacter baumannii is a common pathogen of nosocomial infection in China, and it is generally more problematic. There is no good way to resist all existing drugs, as you said. However, fungal infections can be controlled first, and drugs such as fluconazole, itraconazole, and amphotericin B liposomal can be added.
If well controlled, the condition may take a turn for the better. But in this case, like you said, the prognosis is relatively poor, so you have to be mentally prepared.
-
Promote it more on the Internet, go to various communities, post it, post it, it's really hard for you.
-
The biochemical identification was mainly based on the API-20NE system, and the necessary 5 tests were supplemented. The results showed that the four Acinetobacter species met the general traits of Acinetobacter spp.: oxidase-negative, touchase-positive, non-motility, indole-negative, and non-fermented saccharides Acinetobacter baumannii.
No reduction of nitrates. Percent identification of 72 strains of Acinetobacter baumannii in the API-20NE system (%ID); %ID of 15 strains of Acinetobacter calciconate; The %IDs of the 3 strains of Acinetobacter jeonii were between, with an average of ; The %ID of Acinetobacter lofe strains of 6 strains was between, with an average of .
At present, the drug resistance rate of Acinetobacter is on the rise, some of which are rising rapidly (such as ciprofloxacin), and the drug resistance rate has been maintained at a high level of ampicillin, cefazolin and chloramphenicol. The drug resistance rate is still low, such as imipenem-cilastatin, ceftazidime, cefoperazone-sulbactam, ampicillin-sulbactam, piperacillin-tazobactam and amikacin. In the empirical drug stage, cefoperazone-sulbactam, imipenem-cilastatin are often preferred, and ampicillin-sulbactam, ticarcillin-clavulanate, amikacin, and a new generation of fluoroquinolones are often preferred.
For more severe disease, a combination of -lactams and aminoglycosides (or fluoroquinolones, or rifampicin) is advocated. Then, the regimen was adjusted based on the susceptibility results.
-
In order to hide your shadow for a long time, in the depths of winter, I put another lock on my heart. And now, on this day, I feel like I'm hearing my own voice again in my keyhole! Bonus points, hee-hee.
-
There is a saying, cherished words, I have to say to you, because maybe I can only say it once a year, and I think it's time to say it out loud, and I want to shout ......Happy Chinese New Year :)
-
Let's consult more and see if anyone can provide new drug methods, that's all it takes, it's really hard.
-
When did Meiping become a high-grade imported antibiotic? . .
-
I'm afraid I'll wake up late tomorrow, so I'll book the first ray of sunshine for you now, and I wish you a happy new year! Book the first morning breeze for you and wish you all the best! Book the first birdsong and wish your wishes come true! Bonus points, hee-hee.
I'm afraid I'll wake up late tomorrow, so I'll book the first ray of sunshine for you now, and I wish you a happy new year! Book the first morning breeze for you and wish you all the best! Book the first birdsong and wish your wishes come true! Bonus points, hee-hee.
-
Please find a Chinese medicine doctor as soon as possible.
-
Happy New Year! I wish you to surpass the Virgin Mary in popularity, dare to be the mother of Bill Gates, be more heroic than Saddam, and be handsome to chase Beckham, and you are the only international superman!
-
In October 2012, researchers in the United States reported that they had developed a new antibiotic that could exert an infection-fighting effect by "disarming" Acinetobacter bauernii rather than killing the bacteria. The researchers found that Acinetobacter baumannii call-off strains produce endotoxins during growth, and the more endotoxins there are, the more virulent the strains become. Using a small molecule called LPXC1 to block endotoxin synthesis, rats infected with Acinetobacter baumannii did not accumulate more and more inflammatory immune responses and their symptoms were significantly alleviated.